Stay updated on Elranatamab Combo Therapy in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Elranatamab Combo Therapy in Multiple Myeloma Clinical Trial page.

Latest updates to the Elranatamab Combo Therapy in Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.5.4 is displayed instead of v3.5.3 on the page, indicating a minor system update to the Study History page.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedPfizer terminated the MagnetisMM-4 umbrella study and will not pursue the Phase 2 expansion, changing its status to Terminated; the termination note specifies it was not due to safety concerns or regulatory requests.SummaryDifference0.5%

- Check43 days agoChange DetectedThe page revision label changes from v3.5.0 to v3.5.2, with no other study record content updates shown.SummaryDifference0.1%

- Check72 days agoChange DetectedA new revision entry v3.5.0 was added to the history. An earlier revision v3.4.3 was removed from the list.SummaryDifference0.1%

- Check86 days agoChange DetectedNew revision entry v3.4.3 added to the history. Old revision v3.4.2 removed.SummaryDifference0.1%

- Check100 days agoChange DetectedResult-related sections were added to the record, including Results Posted, Adverse Events, Baseline Characteristics, Participant Flow, and Outcome Measures, consolidating detailed trial data. The previous entry 'Results Submitted' was removed.SummaryDifference0.9%

Stay in the know with updates to Elranatamab Combo Therapy in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab Combo Therapy in Multiple Myeloma Clinical Trial page.